Valuation: Genovis AB

Market Cap 1.42B 144M 129M 118M 108M 203M 13.54B 209M 568M 7.23B 541M 529M 22.81B P/E 2026 *
72.8x
P/E 2027 * 42.2x
Enterprise Value 1.32B 133M 119M 109M 99.69M 188M 12.52B 194M 525M 6.68B 500M 489M 21.1B EV / Sales 2026 *
8.92x
EV / Sales 2027 * 6.86x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day-0.24%
1 week-2.54%
Current month-2.54%
1 month+7.22%
3 months+6.67%
6 months+5.61%
Current year-0.71%
1 week 20.65
Extreme 20.65
22.2
1 month 19.08
Extreme 19.08
22.5
Current year 15.64
Extreme 15.64
23.65
1 year 15.64
Extreme 15.64
23.65
3 years 15.64
Extreme 15.64
53.9
5 years 15.64
Extreme 15.64
90
10 years 2.18
Extreme 2.18
90
Manager TitleAgeSince
Chief Executive Officer 55 04/05/2015
Director of Finance/CFO 42 31/07/2026
Chief Tech/Sci/R&D Officer 42 31/12/2016
Director TitleAgeSince
Director/Board Member 77 31/12/2013
Director/Board Member 65 31/12/2018
Chairman 74 04/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/26 Buy 6,648 0.0101%
01/10/26 Buy

Chairman

45,000 0.0681%
30/09/26 Buy

Chief Executive Officer

28,000 0.0424%
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%-2.54%-4.31%-53.78% 144M
-3.23%+3.51%-12.02%+15.72% 190B
-2.90%+5.45%+13.04%+38.65% 125B
-2.75%+11.65%-7.90%+17.71% 124B
+0.96%+5.15%-38.02%+12.24% 99.31B
-1.80%+0.82%-7.41%+69.42% 63.65B
-0.78%+7.07%+19.44%-18.22% 57.71B
+0.79%+22.65%-5.28%+59.81% 53.26B
-6.98%-14.56%-12.60%+42.69% 47.03B
-2.36%+3.72%+3.27%-8.07% 36.15B
Average -1.93%+4.49%-5.18%+17.62% 79.63B
Weighted average by Cap. -2.20%+5.71%-6.94%+24.47%

Financials

2026 *2027 *
Net sales 148M 14.94M 13.4M 12.25M 11.18M 21.06M 1.4B 21.72M 58.86M 749M 56.07M 54.87M 2.37B 187M 18.94M 16.98M 15.52M 14.17M 26.7M 1.78B 27.54M 74.61M 950M 71.08M 69.56M 3B
Net income 12M 1.21M 1.09M 996K 909K 1.71M 114M 1.77M 4.78M 60.92M 4.56M 4.46M 192M 33.7M 3.41M 3.06M 2.8M 2.55M 4.81M 321M 4.96M 13.44M 171M 12.8M 12.53M 540M
Net Debt -107M -10.83M -9.71M -8.88M -8.1M -15.27M -1.02B -15.75M -42.67M -543M -40.65M -39.78M -1.71B -140M -14.17M -12.71M -11.61M -10.6M -19.98M -1.33B -20.61M -55.82M -711M -53.19M -52.05M -2.24B
Projected Income Statement - Annual - Genovis AB
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
42
Date Price Change Volume
06/11/26 SEK 21.10 -0.24% 168,106
05/11/26 SEK 21.15 0.00% 160,668
04/11/26 SEK 21.15 -0.47% 78,143
03/11/26 SEK 21.25 -0.93% 102,693
02/11/26 SEK 21.45 -0.92% 75,128
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Genovis AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
21.10SEK
Average target price
33.00SEK
Spread / Average Target
+56.40%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genovis AB
  1. Stock Market
  2. Stocks
  3. GENO Stock